TABLE 2.

AD severity assessment at baseline and follow-up after 1 and 4 months on upadacitinib therapy.

Indicator	Baseline (n = 16)	1-month follow-up (n = 16)	4-month follow-up (n = 10)
EASI score Median (min-max) Mean (SD)	28.2 (10.6–60.5) 29.5(14.5)	10.1 (0–22.2) 10.7 (7.6)	2.15 (0–25.5) 5.5 (8.2)
DLQI Median (min-max) Mean (SD)	20.5 (4–29) 19.8 (6.7)	7.5 (0–23) 10.1 (8.0)	4 (0–20) 4.5 (5.9)
BSA Median (min-max)	60 (32–95)	N/A	N/A
NRS-itch Median (min-max) Mean (SD)	9 (5–10) 8.5 (1.6)	2 (0–8) 3.1 (2.9)	N/A
NRS-insomnia Median (min-max) Mean (SD)	7 (0–10) 6.5 (3.5)	1 (0–7) 2.3 (2.8)	N/A

EASI, Eczema Area and Severity Index; SCORAD, Scoring of Atopic Dermatitis; DLQI, Dermatology Life Quality Index; vIGA-AD, Validated Investigator Global Assessment for AD; BSA, body surface area; NRS, numerical rate scale; SD, standard deviation; N/A, not accessed.